AP2015008955A0 - A novel formulation of indomethacin - Google Patents

A novel formulation of indomethacin

Info

Publication number
AP2015008955A0
AP2015008955A0 AP2015008955A AP2015008955A AP2015008955A0 AP 2015008955 A0 AP2015008955 A0 AP 2015008955A0 AP 2015008955 A AP2015008955 A AP 2015008955A AP 2015008955 A AP2015008955 A AP 2015008955A AP 2015008955 A0 AP2015008955 A0 AP 2015008955A0
Authority
AP
ARIPO
Prior art keywords
indomethacin
novel formulation
formulation
novel
Prior art date
Application number
AP2015008955A
Other languages
English (en)
Inventor
Aaron Dodd
Marck Norret
Adrian Russell
Original Assignee
Icuetica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43010611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008955(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2009901745A external-priority patent/AU2009901745A0/en
Application filed by Icuetica Pty Ltd filed Critical Icuetica Pty Ltd
Publication of AP2015008955A0 publication Critical patent/AP2015008955A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AP2015008955A 2009-04-24 2010-04-23 A novel formulation of indomethacin AP2015008955A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17229509P 2009-04-24 2009-04-24
AU2009901745A AU2009901745A0 (en) 2009-04-24 A Novel Formulation of Indomethacin
PCT/AU2010/000472 WO2010121328A1 (fr) 2009-04-24 2010-04-23 Nouvelle formulation d'indométhacine

Publications (1)

Publication Number Publication Date
AP2015008955A0 true AP2015008955A0 (en) 2015-12-31

Family

ID=43010611

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2015008955A AP2015008955A0 (en) 2009-04-24 2010-04-23 A novel formulation of indomethacin
AP2011005992A AP3628A (en) 2009-04-24 2010-04-23 A novel formulation of indomethacin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AP2011005992A AP3628A (en) 2009-04-24 2010-04-23 A novel formulation of indomethacin

Country Status (22)

Country Link
US (8) US20120135048A1 (fr)
EP (1) EP2421513B1 (fr)
JP (3) JP6027890B2 (fr)
KR (3) KR101743847B1 (fr)
CN (2) CN102438594A (fr)
AP (2) AP2015008955A0 (fr)
AU (1) AU2010239081C1 (fr)
BR (1) BRPI1014275B8 (fr)
CA (1) CA2759125C (fr)
CO (1) CO6470807A2 (fr)
DK (1) DK2421513T3 (fr)
EA (1) EA201171286A1 (fr)
IL (2) IL215872A (fr)
MA (1) MA33296B1 (fr)
MX (1) MX351930B (fr)
MY (1) MY159208A (fr)
NZ (3) NZ620879A (fr)
SG (2) SG175315A1 (fr)
TN (1) TN2011000544A1 (fr)
UA (1) UA106231C2 (fr)
WO (1) WO2010121328A1 (fr)
ZA (1) ZA201108646B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007264418B2 (en) 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
SG10201607849TA (en) * 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
JP5898613B2 (ja) * 2009-04-24 2016-04-06 イシューティカ ピーティーワイ リミテッド 生物学的活性物質の溶解プロファイルを改善するための方法
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
US9695390B2 (en) 2010-08-23 2017-07-04 President And Fellows Of Harvard College Acoustic waves in microfluidics
EP2608772A2 (fr) * 2010-08-23 2013-07-03 President and Fellows of Harvard College Particules destinées à l'administration de médicaments et à d'autres applications
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2015200616A1 (fr) 2014-06-26 2015-12-30 President And Fellows Of Harvard College Injection de fluide à l'aide d'ondes acoustiques
CN108472621B (zh) 2015-08-27 2022-04-29 哈佛学院院长及董事 声波分拣
WO2017136617A1 (fr) 2016-02-04 2017-08-10 Cinrx Pharma, Llc Compositions de dompéridone deutérée et méthodes pour la thérapie de troubles
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11701658B2 (en) 2019-08-09 2023-07-18 President And Fellows Of Harvard College Systems and methods for microfluidic particle selection, encapsulation, and injection using surface acoustic waves
EP3804702A1 (fr) * 2019-10-10 2021-04-14 Bayer AG Procédé de fabrication d'une formulation pharmaceutique comprenant un principe actif, un polymère et un tenside
ES2984690T3 (es) * 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas
TR202017034A2 (tr) * 2020-10-26 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172546A (en) 1961-05-19 1965-03-09 Union Carbide Corp Size reduction of biological substances
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4200631A (en) * 1975-12-17 1980-04-29 Richter Gedeon Vegyeszeti Gyar Rt. Treating mammalian subject sensitive to indomethacin ulcerogenisis
IT1082518B (it) 1977-01-25 1985-05-21 Fiat Spa Specchio a cristallo liquido da impiegare particolarmente come retrovisore per veicoli
NL175882C (nl) * 1977-03-28 Procter & Gamble Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DE3312671A1 (de) 1983-04-08 1984-10-11 Heinz Finzer KG, 7880 Bad Säckingen Stanz- und biegewerkzeug-aggregat
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
CA2143263C (fr) 1994-03-02 2002-01-08 Kerry John Hartauer Formulations pharmaceutiques pouvant etre administrees par voie orale
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5631369A (en) 1994-08-31 1997-05-20 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
WO1998035666A1 (fr) 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
CA2301304A1 (fr) * 1997-08-27 1999-03-04 Hexal Ag Nouvelles compositions pharmaceutiques de meloxicam presentant une solubilite et une biodisponibilite ameliorees
JPH11130698A (ja) * 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1066825A1 (fr) 1999-06-17 2001-01-10 The Procter & Gamble Company Produit antimicrobien pour les soins du corps
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP5698423B2 (ja) 2000-06-27 2015-04-08 ベクトゥラ・リミテッド 医薬組成物で使用するための粒子の製造法
JP4969761B2 (ja) 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2001297844A1 (en) 2000-11-20 2002-12-03 Elan Pharma International Ltd. Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
ES2474199T3 (es) 2000-11-30 2014-07-08 Vectura Limited Composiciones farmacéuticas para inhalaci�n
US20030035833A1 (en) 2000-12-06 2003-02-20 Xiaorong He Rapidly dispersing pharmaceutical composition
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
DE60203506T2 (de) 2001-06-22 2006-02-16 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
JP2003066613A (ja) 2001-08-22 2003-03-05 Columbia Music Entertainment Inc スタンパの製造方法
ES2292848T3 (es) 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US6825161B2 (en) 2002-04-26 2004-11-30 Salvona Llc Multi component controlled delivery system for soap bars
AU2003276688A1 (en) 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
EP1832583A1 (fr) 2002-09-30 2007-09-12 A/S GEA Farmaceutisk Fabrik Nouveaux sels d'addition de l'acide raloxifène sulfurique et/ou leurs solvates et compositions pharmaceutiques les comprenant
WO2004058216A2 (fr) 2002-12-17 2004-07-15 Elan Pharma International Ltd. Broyage de quantites de composes candidats nanoparticulaires de l'ordre du microgramme
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
AU2003230189A1 (en) 2003-01-29 2004-08-23 Nitin Bhalachandra Dharmadhikari Oral controlled release pharmaceutical composition containing metaxalone as active agent
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
JP4739217B2 (ja) * 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
DE60309356T2 (de) * 2003-06-27 2007-08-30 Bioprogress S.P.A. Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
ATE415946T1 (de) 2003-08-08 2008-12-15 Elan Pharma Int Ltd Neue metaxalon-zusammensetzungen
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
ES2286674T3 (es) 2003-10-01 2007-12-01 Debio Recherche Pharmaceutique S.A. Dispositivo y procedimiento para la fabricacion de particulas.
EP1686962B9 (fr) 2003-11-05 2012-10-03 Elan Pharma International Limited Compositions nanoparticulaires comprenant un peptide comme stabilisant de surface
US20050276844A1 (en) 2004-03-08 2005-12-15 Spiridon Spireas Bioavailable compositions of metaxalone and processes for producing the same
CA2578709C (fr) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprenant une proteine adherant aux muqueuses et principe actif pour la delivrance d'agents dans des muqueuses
WO2006009419A1 (fr) 2004-07-19 2006-01-26 Luis Cordova Boone Pneus a double bande de roulement
KR20060024927A (ko) 2004-09-15 2006-03-20 씨제이 주식회사 기계적 분쇄법에 의한 미크론 사이즈 인삼 분말의제조방법
WO2006041843A2 (fr) 2004-10-04 2006-04-20 Dr. Reddy's Laboratories Ltd. Forme posologique pharmaceutique comprenant meloxicam
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
CA2598204C (fr) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Composition de petites particules medicamenteuses chauffee et stabilisee
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
EP1830824B1 (fr) 2004-12-31 2016-01-13 Iceutica Pty Ltd. Composition de nanoparticules et procedes de synthese de cette derniere
JP2008540546A (ja) 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US20080292584A1 (en) 2005-10-14 2008-11-27 Mutual Pharmaceutical Company, Inc. Metaxalone products, method of manufacture, and method of use
DK1973527T3 (da) 2005-12-15 2010-02-01 Acusphere Inc Fremgangsmåder til fremstilling af partikelbaserede farmaceutiske formulationer til parenteral indgivelse
EP1978933A2 (fr) 2005-12-15 2008-10-15 Acusphere, Inc. Procédés de préparation de formulations pharmaceutiques à base de particules destinées à une administration orale
CA2631493A1 (fr) * 2005-12-15 2007-06-21 Acusphere, Inc. Procedes d'elaboration de preparations pharmaceutiques a base de particules pour administration pulmonaire ou nasale
WO2007074477A2 (fr) 2005-12-29 2007-07-05 Dabur Pharma Limited Polymorphes de métaxalone
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
ATE502629T1 (de) 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
EP2032139A4 (fr) 2006-06-23 2012-08-22 Elan Pharma Int Ltd Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée
AU2007264418B2 (en) * 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
NZ705763A (en) 2006-06-30 2016-10-28 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CN100386312C (zh) 2006-07-18 2008-05-07 上海世景国际贸易有限公司 2，4-二氨基苯磺酸及其盐的合成方法
KR20090027734A (ko) 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
TWI405590B (zh) * 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
AR067997A1 (es) 2007-08-24 2009-10-28 Novartis Ag Compuestos organicos
US8568696B2 (en) 2008-08-06 2013-10-29 Indiana Nanotech Llc Grinding method for the manipulation or preservation of calcium phosphate hybrid properties
EA201171284A1 (ru) 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Новая технология изготовления напроксена
KR101580656B1 (ko) 2009-04-24 2015-12-30 아이슈티카 피티와이 리미티드 디클로페낙의 신규 제형
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
JP5898613B2 (ja) 2009-04-24 2016-04-06 イシューティカ ピーティーワイ リミテッド 生物学的活性物質の溶解プロファイルを改善するための方法
MX360019B (es) 2009-04-24 2018-10-15 Iceutica Pty Ltd Una formulación novedosa de metaxalona.
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
AP2015008967A0 (en) 2009-04-24 2015-12-31 Iceutica Pty Ltd A novel formulation of meloxicam
AP3138A (en) 2009-04-24 2015-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
SG10201607849TA (en) 2009-04-24 2016-11-29 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
JP2011005735A (ja) 2009-06-25 2011-01-13 Olympus Corp 画像記録装置及び画像記録装置の初期化制御方法

Also Published As

Publication number Publication date
BRPI1014275A2 (pt) 2016-10-18
KR101743847B1 (ko) 2017-06-05
BRPI1014275B8 (pt) 2021-05-25
AP3628A (en) 2016-03-08
ZA201108646B (en) 2013-01-30
US20180117008A1 (en) 2018-05-03
KR20120101285A (ko) 2012-09-13
AU2010239081A1 (en) 2011-11-10
WO2010121328A1 (fr) 2010-10-28
SG10201401695VA (en) 2014-08-28
US20140255494A1 (en) 2014-09-11
SG175315A1 (en) 2011-11-28
US8992982B2 (en) 2015-03-31
UA106231C2 (uk) 2014-08-11
IL247034A (en) 2017-07-31
MX351930B (es) 2017-11-03
US9095496B2 (en) 2015-08-04
KR20150030782A (ko) 2015-03-20
AU2010239081B2 (en) 2014-06-12
CO6470807A2 (es) 2012-06-29
IL215872A (en) 2016-08-31
EA201171286A1 (ru) 2012-05-30
DK2421513T3 (en) 2018-03-26
TN2011000544A1 (en) 2013-05-24
EP2421513A4 (fr) 2012-12-05
BRPI1014275B1 (pt) 2020-09-15
JP6239709B2 (ja) 2017-11-29
CN103932988A (zh) 2014-07-23
NZ710384A (en) 2017-03-31
US20140256781A1 (en) 2014-09-11
JP2012524724A (ja) 2012-10-18
US20170095448A1 (en) 2017-04-06
JP2017019848A (ja) 2017-01-26
JP6027890B2 (ja) 2016-11-16
AP2011005992A0 (en) 2011-12-31
CN102438594A (zh) 2012-05-02
US10172828B2 (en) 2019-01-08
NZ595986A (en) 2014-04-30
US20130243854A1 (en) 2013-09-19
US20160022637A1 (en) 2016-01-28
JP2015051995A (ja) 2015-03-19
US9089471B2 (en) 2015-07-28
US8734847B2 (en) 2014-05-27
NZ620879A (en) 2015-08-28
KR20140077945A (ko) 2014-06-24
MY159208A (en) 2016-12-30
US20120135048A1 (en) 2012-05-31
US9522135B2 (en) 2016-12-20
EP2421513B1 (fr) 2017-12-13
JP6043329B2 (ja) 2016-12-14
EP2421513A1 (fr) 2012-02-29
US9849111B2 (en) 2017-12-26
IL215872A0 (en) 2012-01-31
CA2759125A1 (fr) 2010-10-28
CA2759125C (fr) 2017-08-15
AU2010239081C1 (en) 2014-11-06
US20140194487A1 (en) 2014-07-10
MA33296B1 (fr) 2012-05-02
MX2011011226A (es) 2012-02-08

Similar Documents

Publication Publication Date Title
AP3628A (en) A novel formulation of indomethacin
AP3774A (en) A novel formulation of diclofenac
SG10201401720RA (en) A novel formulation of naproxen
EP2339918A4 (fr) Préparation d'un quinolinyloxydiphénylcyclopropanedicarboxamide
AP3659A (en) A novel formulation of meloxicam
ZA201108644B (en) A novel formulation of metaxalone
GB0907003D0 (en) Formulation
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
EP2459540A4 (fr) Préparation du fipamézole
GB0917775D0 (en) Novel pharmaceutical compounds
GB0911213D0 (en) Formulation
GB0907410D0 (en) Formulation
GB0917774D0 (en) Novel pharmaceutical compounds
AU2009901745A0 (en) A Novel Formulation of Indomethacin
IL257014A (en) A novel formulation of meloxicam
IL256841B (en) A novel formulation of metaxalone
GB0915468D0 (en) Get me out of here
GB0904499D0 (en) A set of parts
GB0901420D0 (en) Formula 1-2050
GB0906291D0 (en) Formulation
GB0902472D0 (en) Formulation
GB0905280D0 (en) Novel uses of VEGFxxxb
GB0903773D0 (en) Works of art
GB0919237D0 (en) Improvements of a device
GB0902525D0 (en) Pharmacophores